Novel Therapies for Chronic Autoimmune Diseases | Nuvig Therapeutics

Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases

We Are Pioneering Autoimmune Therapies for a New Standard of Care

At Nuvig Therapeutics, our mission is to change the treatment paradigm for patients with autoimmune disease. We acknowledge the urgent need to provide next-generation immune modulators that treat the underlying inflammatory disease without compromising immune function.

Our Science

A Novel Approach

Nuvig Therapeutics is a scientifically-driven organization focusing on translating novel therapeutic insights to develop innovative medicine for autoimmune diseases. Our core technology harnesses an endogenous regulatory mechanism that resolves autoimmune dysregulation.

Our Pipeline

We Are a Dedicated Team

Join our team of dedicated scientists and experienced drug developers. We are committed to developing innovative therapies and improving the quality of life for patients with chronic inflammatory and autoimmune diseases.

Join Us

September 9, 2025

Nuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair

Read More

May 14, 2025

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data

Read More

December 5, 2024

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Read More